References: |
1. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ, Huganir RL, Hemmings HC, Jr., Nairn AC, Greengard P (1999) Phosphorylation of DARPP-32 by cdk5 modulates dopamine signalling in neurons. Nature (London) 402:669-671. 2. Fienberg, A.A., Hiroi, N., Mermelstein, P.G., Song, W., Snyder, G.L., Nishi, A., Cheramy, A. O'Callaghan, J.P., Miller, D.B., Cole, D.G., Corbett, R., Haile, C.N., Cooper, D,C., Onn, S.P., Grace, A.A., Ouimet, C.C., White, F.G., Hyman, S.E., Surmeier, D.G., Girault, J., Nestler, E.J. and Greengard, P. (1998) DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281:838-842. 3. Lindskog M, Svenningsson P, Pozzi L, Kim Y, Fienberg AA, Bibb JA, Fredholm BB, Nairn AC, Greengard P, Fisone G (2002) Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature (London) 418:774-778. 4. Maldve RE, Zhang TA, Ferrani-Kile K, Schreiber SS, Lippmann MJ, Snyder GL, Feinberg AA, Leslie SW, Gonzales RA, Morrisett RA (2002) DARPP-32 and the regulation of the ethanol sensitivity of NMDA receptors in the nucleus accumbens. Nature Neurosci 5:641-648. 5. Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG, Greengard P (2002) Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac(R)). Proc Natl Acad Sci USA 99:3182-3187. |